Advertisement


Mario E. Lacouture, MD, on Management of Dermatologic Toxicities Associated With Targeted Therapies

2015 NCCN Annual Conference

Advertisement

Mario E. Lacouture, MD, of Memorial Sloan Kettering Cancer Center, discusses the effect on patients of dermatologic toxicities associated with targeted therapies: their psychosocial impact, financial burden, physiological pain, and potential to alter therapy. But the side effects of targeted treatments can and should be addressed.



Related Videos

Issues in Oncology

Mary Lou Smith, JD, MBA, on the Value of NCCN Guidelines to Patients and Their Advocates

Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on cancer care.

Lung Cancer

Leora Horn, MD, MSc, on Targeted and Emerging Therapies for Metastatic NSCLC

Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, discusses the range of treatment options for people with lung cancer, including third generation inhibitors, and the key clinical trials studying alternatives for patients with acquired resistance.

Lung Cancer

John C. Grecula, MD, on the Role of Radiation Therapy in Management of SCLC

John C. Grecula, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of precision delivery of radiation for patients with small cell lung cancer and advances that include prophylactic cranial radiotherapy, thoracic radiotherapy, and the use of PET-CT.

Gynecologic Cancers

Wui-Jin Koh, MD, on Making NCCN Guidelines Relevant Around the Globe

Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance, discusses the program to adapt NCCN guidelines to regions of the world with different resource availability. The first guideline to be adapted in this way is for cervical cancer, which is prevalent in the developing world.

Breast Cancer

Amy Cyr, MD on Advances in Management of Early-Stage Breast Cancer

Amy Cyr, MD, of the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, discusses advances made in the treatment of early-stage breast cancer: less radiation and a shorter course, the rising use of molecular profiling, and less invasive surgery and reduced amounts of surgery.

Advertisement

Advertisement




Advertisement